Figure 1From: Improvements in patient-reported outcomes with apremilast, an oral phosphodiesterase 4 inhibitor, in the treatment of moderate to severe psoriasis: results from a phase IIb randomized, controlled study Mean change from baseline in SF-36 physical and mental component summary scores at week 16. P values (vs. placebo), based on ANCOVA, with treatment as the factor, and baseline value as the covariate. An increase in score indicates improvement. MCID, minimal clinically important difference; SF-36, 36-item Short-Form Health Survey.Back to article page